RxDoctor Payments Data

Jeffery Lee, MD

Internal Medicine · Mission Hills, CANPI 1205855848

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 50 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$195
  • Novo Nordisk$195
  • Merck$158
  • AbbVie$138
  • E.r. Squibb & Sons, L.L.C.$62
  • Abbott$55
  • plus $216 from 8 others

What the payments were for

  • Food & beverage$1,019100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,019 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$33,305
Medicare patients
95
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban97$119,669
JardianceEmpagliflozin47$50,950
OzempicSemaglutide46$49,985
TrulicityDulaglutide26$34,806
JanuviaSitagliptin Phosphate20$32,780
MounjaroTirzepatide14$20,223
Spiriva HandihalerTiotropium Bromide30$20,142
XareltoRivaroxaban16$14,128
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$7,782
MyrbetriqMirabegron12$7,451
Atorvastatin Calcium540$6,413
TrintellixVortioxetine Hydrobromide11$5,422
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,411
Levothyroxine Sodium246$3,388
Losartan Potassium261$3,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$195$119,66997 claims
Lilly USA, LLCTrulicity, Mounjaro$25$55,02940 claims
Novo NordiskOzempic$195$49,98546 claims
MerckJanuvia$158$32,78020 claims
AbbVieSynthroid$138$99927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →